U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06881836) titled 'A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease' on March 02.
Brief Summary: This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
DRUG: ONO-2020
ONO...